Cxbladder is a Genomic Urine Test for Bladder Cancer

Cxbladder is a cutting-edge genomic urine test that quickly and accurately detects or rules out bladder cancer. The test works at a molecular level, measuring five biomarker genes to detect the presence or absence of bladder cancer.

Reliable: Cxbladder utilises high sensitivity and negative predictive value to either help rule out the disease or complement other diagnostic procedures and tests to improve overall detection accuracy.

Clinically proven: Proven performance in 10 peer-reviewed publications for primary detection, surveillance, and adjudicating atypical cytology. 65% of the New Zealand population now have access to Cxbladder via public healthcare, with more DHBs expected to follow soon.

Non-invasive and easy-to-use: Cxbladder’s unique urine sample collection system is discrete, non-invasive and easy-to-use, taking only minutes.

In-home sampling: To streamline patient care we are now offering an in-home sampling service to both haematuria and surveillance patients.

Quick: Upon receiving a urine sample, our certified NZ laboratory will provide actionable results in 5 days.

A Suite of Tests Optimised to Primary Detection and Surveillance

Cxbladder comes as a suite of three products each optimised for a specific point along the patient journey.

cxbladder family of products

Cxbladder Triage

Designed for patients presenting with haematuria. Cxbladder Triage analyses the presence of five biomarker genes alongside information on known bladder cancer risk factors like age, gender and smoking history to rule out patients with a low risk of having the disease.

Cxbladder Triage provides accurate results and reassurance that can reduce the need for further invasive procedures.

Cxbladder Detect

In cases where a patient is symptomatic and bladder cancer looks likely, Cxbladder Detect can help confirm your diagnosis.

By detecting and quantifying signs of cancer at the molecular level, Cxbladder Detect outperforms other urine-based tests, making it an ideal choice for bladder cancer testing when patients present with significant symptoms. Cxbladder Detect can also be used as an adjunct to cystoscopy or as a substitute for other radiological tests to improve overall detection accuracy.

Cxbladder Monitor

Developed specifically for patients undergoing surveillance for recurrent bladder cancer. The test combines clinical information linked to previous bladder cancer with measured biomarker genes to help rule out the presence of a recurrent tumour, or to indicate that further clinical investigation is required.

Cxbladder Monitor can provide accurate results with a single urine sample, and test is often used as a non-invasive monitoring alternative to reduce the need for frequent cystoscopies.
Request More Info on Triage, Detect or Monitor

Cxbladder In-Home Sampling is Available

Cxbladder’s unique urine sampling system is non-invasive and easy-to-use. The process is quick and painless, taking only minutes.

To simplify and streamline the bladder cancer testing process, we are now offering in-home sampling for patients around the country. Patients have the option of submitting their Cxbladder urine sample in the comfort of their own home without the need to physically visit a clinic.
Learn More

The Difference in Cancer Detection

Cxbladder is a reliable test for bladder cancer that can help you make informed treatment and care decisions.

Most symptomatic or surveillance patients do not have bladder cancer. Cxbladder enables the accurate rule out of patients with haematuria and those being monitored for recurrence, reducing the burden of cystoscopy and sparing patients anxiety and discomfort. The test also solves a diagnostic dilemma, accurately resolving atypical cytology and equivocal cystoscopy in the evaluation of patients presenting with haematuria or being monitored for recurrence.
Contact Us to Request More Information

Last Updated: 29 Oct 2020 09:30 am

  • References

    Cxbladder was developed by a company whose passion and focus is cancer diagnostics and prognostics to improve patient outcomes. See our full list of clinical publications.

    Pacific Edge is responsible for the development and determination of the performance characteristics for Cxbladder. Because Cxbladder is a Laboratory Developed Test (LDT), Cxbladder has not been cleared or approved by the US Food and Drug Administration (FDA).

Diagnosing bladder cancer

Dr Rod Studd discusses the guidelines, issues and technologies for diagnosing UC in patients presenting with hematuria in primary care.

Diagnosing bladder cancer
Diagnosing bladder cancer